{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:28:21Z","timestamp":1776194901964,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI068636"],"award-info":[{"award-number":["AI068636"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI068634"],"award-info":[{"award-number":["AI068634"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI106701"],"award-info":[{"award-number":["AI106701"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI169768"],"award-info":[{"award-number":["AI169768"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jcv.2026.105930","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:16:27Z","timestamp":1772525787000},"page":"105930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterization of HIV humoral immunity during analytical treatment interruption"],"prefix":"10.1016","volume":"183","author":[{"given":"Clara","family":"Di Germanio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan G.","family":"Balasko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia G.","family":"Villaflor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Noutsios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh T.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcv.2026.105930_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The biology of the HIV-1 latent reservoir and implications for cure strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.jcv.2026.105930_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrmicro.2015.5","article-title":"HIV reservoirs: what, where and how to target them","volume":"14","author":"Churchill","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"issue":"7","key":"10.1016\/j.jcv.2026.105930_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007229","article-title":"Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers","volume":"15","author":"Conway","year":"2019","journal-title":"PLOS Comput. Biol."},{"issue":"10","key":"10.1016\/j.jcv.2026.105930_bib4","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/infdis\/jit667","article-title":"HIV antibody characterization as a method to quantify reservoir size during curative interventions","volume":"209","author":"Burbelo","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.jcv.2026.105930_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/QAI.0000000000002080","article-title":"Brief report: HIV antibodies decline during antiretroviral therapy but remain correlated with HIV DNA and HIV-specific T-Cell responses","volume":"81","author":"Keating","year":"2019","journal-title":"J. Acquir Immune Defic. Syndr. 1999"},{"issue":"1","key":"10.1016\/j.jcv.2026.105930_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/infdis\/jix225","article-title":"HIV antibody level as a marker of HIV persistence and low-level viral replication","volume":"216","author":"Keating","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jcv.2026.105930_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00170-21","article-title":"Viral rebound kinetics correlate with distinct HIV antibody features","volume":"12","author":"Bartsch","year":"2021","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.jcv.2026.105930_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173864","article-title":"Predictors of HIV rebound differ by timing of antiretroviral therapy initiation","volume":"9","author":"Li","year":"2024","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.jcv.2026.105930_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciab541","article-title":"Time to viral rebound after interruption of modern antiretroviral therapies","volume":"74","author":"Li","year":"2021","journal-title":"Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am."},{"issue":"7","key":"10.1016\/j.jcv.2026.105930_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220345","article-title":"Performance comparison of the Maxim and Sedia limiting antigen avidity assays for HIV incidence surveillance","volume":"14","author":"Sempa","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jcv.2026.105930_bib11","doi-asserted-by":"crossref","DOI":"10.2196\/34410","article-title":"Use of HIV recency assays for HIV incidence estimation and other surveillance use cases: systematic review","volume":"8","author":"Facente","year":"2022","journal-title":"JMIR Public Health Surveill."},{"issue":"4","key":"10.1016\/j.jcv.2026.105930_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/QAI.0000000000001421","article-title":"Impact of early antiretroviral therapy on the performance of HIV rapid tests and HIV incidence assays","volume":"75","author":"Fogel","year":"2017","journal-title":"J. Acquir Immune Defic. Syndr. 1999"},{"key":"10.1016\/j.jcv.2026.105930_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107222","article-title":"Suppressed HIV antibody responses following exposure to antiretrovirals\u2014evidence from PrEP randomized trials and early antiretroviral treatment initiation studies","volume":"148","author":"Avelino-Silva","year":"2024","journal-title":"Int J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.jcv.2026.105930_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/v14071426","article-title":"The impact of early antiretroviral treatment (ART) for HIV on the sensitivity of the latest generation of blood screening and point of care assays","volume":"14","author":"Vermeulen","year":"2022","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.jcv.2026.105930_bib15","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/v16101588","article-title":"Interventions during early infection: opening a window for an HIV cure?","volume":"16","author":"Hiner","year":"2024","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.jcv.2026.105930_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"INSIGHT START Study Group","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.jcv.2026.105930_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw100","article-title":"Antibody responses after analytic treatment interruption in human immunodeficiency Virus-1-infected individuals on early initiated antiretroviral therapy","volume":"3","author":"Stephenson","year":"2016","journal-title":"Open Forum Infect. Dis."},{"issue":"25","key":"10.1016\/j.jcv.2026.105930_bib18","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/blood-2010-05-285528","article-title":"B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy","volume":"116","author":"Moir","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcv.2026.105930_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.188.2.233","article-title":"HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy","volume":"188","author":"Morris","year":"1998","journal-title":"J. Exp. Med"},{"issue":"8","key":"10.1016\/j.jcv.2026.105930_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-1293.2006.00406.x","article-title":"Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection","volume":"7","author":"Adalid-Peralta","year":"2006","journal-title":"HIV Med"},{"issue":"2","key":"10.1016\/j.jcv.2026.105930_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/QAI.0b013e318120039b","article-title":"Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies","volume":"46","author":"Selleri","year":"2007","journal-title":"J. Acquir Immune Defic. Syndr. 1999"},{"issue":"2","key":"10.1016\/j.jcv.2026.105930_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0b013e3181743980","article-title":"The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department","volume":"48","author":"Laeyendecker","year":"2008","journal-title":"J. Acquir Immune Defic. Syndr. 1999"},{"issue":"8","key":"10.1016\/j.jcv.2026.105930_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160192","article-title":"Anti-HIV antibody responses and the HIV reservoir size during antiretroviral therapy","volume":"11","author":"Lee","year":"2016","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.jcv.2026.105930_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11904-019-00432-x","article-title":"The antibodiome\u2014mapping the humoral immune response to HIV","volume":"16","author":"Butler","year":"2019","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"11","key":"10.1016\/j.jcv.2026.105930_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176673","article-title":"Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1","volume":"134","author":"Whitehill","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.jcv.2026.105930_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/COH.0b013e32832f00c0","article-title":"HIV-1-specific antibody responses during acute and chronic HIV-1 infection","volume":"4","author":"Tomaras","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"3","key":"10.1016\/j.jcv.2026.105930_bib27","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JCM.41.3.1016-1022.2003","article-title":"p24 antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection","volume":"41","author":"Sutthent","year":"2003","journal-title":"J. Clin. Microbiol"},{"issue":"5","key":"10.1016\/j.jcv.2026.105930_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/infdis\/159.5.822","article-title":"The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker","volume":"159","author":"Spector","year":"1989","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.jcv.2026.105930_bib29","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/jac\/dkab060","article-title":"Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study)","volume":"76","author":"Mastrangelo","year":"2021","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T18:38:51Z","timestamp":1776191931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653226000193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":29,"alternative-id":["S1386653226000193"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105930","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of HIV humoral immunity during analytical treatment interruption","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105930"}}